The Future of BioPharma - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Future of BioPharma
Innovation resulting in improved productivity continues unabated and is a primary driver for many of the current biopharmaceutical trends. Innovation speeds discovery, drives down costs, and improves productivity.


Pharmaceutical Technology


Key micro-trends

Biosimilars

  • Expect more models and analytical methods for demonstrating biosimilarity and biochemical or biophysical characterization
  • Expect more established regulations, definitions, and standards for biosimilars and biosimilarity
  • Expect bioprocess tweaks allowing for fine-tuning of biosimilars to match innovator biologics
  • Expect more quality by design and design of experiments (DoE) for all products including biosimilars

Analytical methods; assays

  • Expect simpler assay processes that increase process knowledge and speed/simplify product release
  • Expect more convenient, high-throughput assays that assess physicochemical properties of IgG /mAb clones for high level expression and therapeutic efficacy
  • Expect more assays to demonstrate biosimilarity and analytics to demonstrate equivalent product quality

Biomanufacturing process improvements

  • Expect to do more with less—higher workloads, fewer staff, with demands for higher quality and shorter timeframes
  • Improved processing (especially downstream) will better handle 10g/L and greater expression levels
  • Improved upstream process efficiency will incrementally reduce costs, increase productivity while ensuring compliance and quality

Biomanufacturing downstream process improvements

  • Alternatives to Protein A will continue to be sought and developed
  • Need for better performing chromatography resins
  • Development of non-chromatographic recovery unit operations
  • Single-use equipment will make more inroads in downstream processing

Single-use biomanufacturing

  • More quality will be built into single-use systems and operations to further reduce regulatory activities/oversight
  • Problems of disposable bioreactors and devices will be addressed that are creating inconsistent growth because of changes in resins, film gamma irradiation, and cell line specificity
  • Expect more single-use downstream operations using membrane adsorbers
  • Expect emergence of flexible and modular biomanufacturing facilities
  • Expect better standards for leachables and extractables testing and for cell growth
  • Single-use devices facilitating large-scale bioproduction in China and other lesser-developed countries

Regulatory compliance

  • Expect processes and technologies that support lower costs of clinical and commercial supplies
  • Expect more continuous validation programs that link process development and manufacturing data
  • Expect more implementation of process controls such as process analytical technology (PAT)

Supply chain, raw materials; control and sourcing

  • Expect more development of international regulations for quality and raw materials sourcing
  • Expect more process controls that reduce impact of process or raw materials changes on quality
  • Expect decreased product defects as manufacturing facilities increase process control while lowering production costs.

Eric Langer, is president of BioPlan Associates, tel. 301.921.5979,
.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
13%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here